Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 5.6% – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price fell 5.6% during trading on Friday. The stock traded as low as $36.00 and last traded at $36.00. 200 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 2,603 shares. The stock had previously closed at $38.12.

Analyst Ratings Changes

ZLDPF has been the subject of several recent analyst reports. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Finally, Barclays downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Down 4.1%

The business’s fifty day moving average price is $46.05 and its 200 day moving average price is $46.28. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $2.58 billion, a PE ratio of 5.97 and a beta of 0.95.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.